Adverse effects of topical glucocorticosteroids.

By U. Hengge, T. Ruzicka, R. Schwartz, M. Cork. Journal of American Academy of Dermatology, 2006

1,072 citations recorded by the source corpus.

Subfields: Accounting, Demography, Economics and Econometrics

View Paper: https://www.semanticscholar.org/paper/d7e7e04365fb6345169de8dbd321fe6ba0727fb7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Simpson
2. R. Sidbury
3. W. Tom
4. D. Margolis
5. Hywel C. Williams
6. J. Bergman
7. J. Block
8. D. Davis

Citations in the corpus

• A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy (2013, background): “It is important to recognize that inhaled, topical and intraocular GCs may also be absorbed systemically to the degree that they can cause AS [24-26].”
• Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. (2014, background): “Hyperglycemia and hypertension have rarely been reported.(57,66) A systematic review concluded that TCS overall have a good safety profile.”
• Guidelines of Care for the Management of Atopic Dermatitis Part 4: Prevention of Disease Flares and Use of Adjunctive Therapies and Approaches (2014, background): “Hyperglycemia and hypertension have rarely been reported.(57,66) A systematic review concluded that TCS overall have a good safety profile.”